• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

治疗药物监测在检测癌症患者低药物依从性中的意义：卡博替尼的病例研究

The significance of therapeutic drug monitoring in detecting low medication adherence in patients with cancer: A case study of cabozantinib.

作者信息

Maruyama Shinichi, Momo Kenji, Anno Tadatsugu, Ishida Masaru, Kanno Hiroshi, Kato Masaru

机构信息

Department of Bioanalytical Chemistry Showa University Graduate School of Pharmacy Shinagawa-ku Japan.

Department of Pharmacy Saiseikai Yokohamashi Tobu Hospital Yokohama city Japan.

出版信息

Clin Case Rep. 2024 Sep 20;12(9):e9462. doi: 10.1002/ccr3.9462. eCollection 2024 Sep.

DOI:10.1002/ccr3.9462
PMID:39308660
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11413627/
Abstract

Maintaining good medication adherence is important for providing desirable outcomes from medication therapy. We showed that therapeutic drug monitoring (TDM) contributed to the identification of low medication adherence to cabozantinib in a patient with cancer. We present an educational case to assist with understanding TDM in a patient with cancer.

摘要

维持良好的药物依从性对于实现药物治疗的理想效果至关重要。我们发现，治疗药物监测（TDM）有助于识别一名癌症患者对卡博替尼的低药物依从性。我们展示一个教学案例，以帮助理解癌症患者的TDM。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b71/11413627/61ba7e67c948/CCR3-12-e9462-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b71/11413627/31193f4317f6/CCR3-12-e9462-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b71/11413627/61ba7e67c948/CCR3-12-e9462-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b71/11413627/31193f4317f6/CCR3-12-e9462-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b71/11413627/61ba7e67c948/CCR3-12-e9462-g001.jpg

相似文献

1
The significance of therapeutic drug monitoring in detecting low medication adherence in patients with cancer: A case study of cabozantinib.治疗药物监测在检测癌症患者低药物依从性中的意义：卡博替尼的病例研究
Clin Case Rep. 2024 Sep 20;12(9):e9462. doi: 10.1002/ccr3.9462. eCollection 2024 Sep.
2
A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma.一种简单、快速的液相色谱-质谱法测定血浆中卡博替尼的方法：在肾癌患者治疗药物监测中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Feb 1;1138:121968. doi: 10.1016/j.jchromb.2020.121968. Epub 2020 Jan 7.
3
Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.比较新开发的高效液相色谱法与二极管阵列检测法和液相色谱串联质谱法，用于人血清中卡博替尼、达布拉非尼、尼罗替尼和奥希替尼的定量检测——应用于治疗药物监测。
Clin Biochem. 2022 Jul-Aug;105-106:35-43. doi: 10.1016/j.clinbiochem.2022.04.011. Epub 2022 Apr 26.
4
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.多中心观察性研究：酪氨酸激酶抑制剂治疗肺癌患者的依从性、生活质量和不良事件。
J Oncol Pharm Pract. 2021 Jul;27(5):1147-1158. doi: 10.1177/1078155220946381. Epub 2020 Aug 3.
5
Assessment of patient and provider attitudes towards therapeutic drug monitoring to improve medication adherence in low-income patients with hypertension: a qualitative study.评估患者和提供者对治疗药物监测的态度，以提高低收入高血压患者的药物依从性：一项定性研究。
BMJ Open. 2020 Nov 27;10(11):e039940. doi: 10.1136/bmjopen-2020-039940.
6
Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.治疗药物监测指导下的耐药性高血压患者用药依从性特征定义及不依从性的预测因素分析。
Br J Clin Pharmacol. 2018 Nov;84(11):2535-2543. doi: 10.1111/bcp.13706. Epub 2018 Aug 15.
7
Therapeutic monitoring of anti-seizure medications in low- and middle-income countries: a systematic review.低收入和中等收入国家抗癫痫药物的治疗监测：一项系统评价
Wellcome Open Res. 2024 Jan 31;6:92. doi: 10.12688/wellcomeopenres.16749.2. eCollection 2021.
8
Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.转移性肾细胞癌中酪氨酸激酶抑制剂的治疗药物监测。
Clin Genitourin Cancer. 2024 Jun;22(3):102064. doi: 10.1016/j.clgc.2024.102064. Epub 2024 Mar 8.
9
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.转移性肾细胞癌患者卡博替尼的群体药代动力学：向节省药物费用方案迈进。
Clin Pharmacokinet. 2024 Jun;63(6):857-869. doi: 10.1007/s40262-024-01379-y. Epub 2024 Jun 14.
10
Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan.日本慢性髓性白血病患者治疗药物监测和伊马替尼依从性的流行情况。
Int J Clin Pharmacol Ther. 2022 Nov;60(11):469-476. doi: 10.5414/CP204259.

本文引用的文献

1
Quantitative determination of plasma cabozantinib concentration using HPLC-UV and its application to patients with renal cell carcinoma.采用 HPLC-UV 法对卡博替尼的血浆浓度进行定量测定及其在肾癌患者中的应用。
Biomed Chromatogr. 2023 May;37(5):e5599. doi: 10.1002/bmc.5599. Epub 2023 Feb 21.
2
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.酪氨酸激酶抑制剂治疗晚期肾癌的治疗药物监测
Cancers (Basel). 2023 Jan 3;15(1):313. doi: 10.3390/cancers15010313.
3
Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma.
卡博替尼暴露量对不可切除肝细胞癌患者蛋白尿和肌肉毒性的影响
Pharmaceuticals (Basel). 2022 Nov 25;15(12):1460. doi: 10.3390/ph15121460.
4
Small molecule inhibitors targeting the cancers.靶向癌症的小分子抑制剂。
MedComm (2020). 2022 Oct 13;3(4):e181. doi: 10.1002/mco2.181. eCollection 2022 Dec.
5
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.卡博替尼药代动力学、进展和转移性肾细胞癌患者毒性的相关性：药代动力学/药效学研究结果。
ESMO Open. 2021 Dec;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 1.
6
Inhibition and induction of CYP enzymes in humans: an update.在体 CYP 酶的抑制与诱导：更新
Arch Toxicol. 2020 Nov;94(11):3671-3722. doi: 10.1007/s00204-020-02936-7. Epub 2020 Oct 27.
7
Clinical implications of food-drug interactions with small-molecule kinase inhibitors.小分子激酶抑制剂的食物-药物相互作用的临床意义。
Lancet Oncol. 2020 May;21(5):e265-e279. doi: 10.1016/S1470-2045(20)30069-3.
8
Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.探索性研究肾癌患者帕唑帕尼的目标浓度范围。
Clin Genitourin Cancer. 2019 Apr;17(2):e306-e313. doi: 10.1016/j.clgc.2018.12.001. Epub 2018 Dec 7.
9
Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence.针对不依从性的生化筛查与血压降低及依从性改善相关。
Hypertension. 2017 Nov;70(5):1042-1048. doi: 10.1161/HYPERTENSIONAHA.117.09631. Epub 2017 Aug 28.
10
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.对HIV阳性患者中增效蛋白酶抑制剂进行治疗药物监测：血浆浓度不可测与病毒学失败风险
J Antimicrob Chemother. 2017 Jun 1;72(6):1741-1744. doi: 10.1093/jac/dkx052.